Enhancement of cellular immune response in HIV-1 seropositive individuals : A DNA-based trial
Copyright 1999 Academic Press.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 90(1999), 1 vom: 27. Jan., Seite 100-7 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , , , , , , , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
1999
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Clinical Trial Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. AIDS Vaccines Chemokine CCL3 Chemokine CCL4 Chemokine CCL5 HIV Antibodies mehr... |
| Zusammenfassung: | Copyright 1999 Academic Press. A DNA-based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15 HIV-infected asymptomatic patients with CD4-positive lymphocyte counts >/=500/microl of blood and receiving no antiviral therapy. Successive groups of patients received three doses of vaccine at 30, 100, or 300 microg at 10-week intervals in a dose-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV-1 envelope was observed in multiple patients. Three of three patients in the 300-microg dose group also developed increased MIP-1alpha levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increases in any immune parameters were contained within the 300 microg, which was the highest dose group. These studies support further investigation of this technology for the production of antigen-specific immune responses in humans |
|---|---|
| Beschreibung: | Date Completed 05.03.1999 Date Revised 15.11.2007 published: Print Citation Status MEDLINE |
| ISSN: | 1521-7035 |